Replies to post #234681 on Biotech Values

[DewDiligence]

BMY settles US Revlimid-patent case with another challenger—Sun Pharma—on similar terms to prior settlements—(e.g. #msg-158350306):

https://www.fiercepharma.com/manufacturing/bristol-myers-settles-sun-pharma-for-limited-revlimid-generic-launch-2022

The basic framework of these settlements is: a) the generic-drug companies who settled can launch limited quantities their Revilimid generics in the US market in 2022 (Mar 2022 for Natco [the first company to settle with BMY], somewhat later for RDY, and somewhat later for Sun Pharma); and 2) the generic-drug companies who settled can launch unlimited quantities of their Revlimid generics starting on 1/31/26.